CLINICAL CHARACTERISTICS AND OUTCOME OF VENTILATOR ASSOCIATED PNEUMONIA IN PATIENTS WITH RENAL FAILURE
DOI:
https://doi.org/10.61529/idjp.v32i3.232Abstract
Background: Ventilator associated pneumonia (VAP) causes significant morbidity and mortality. Data from patients with preexisting renal failure is limited. Our aim was to evaluate the clinical characteristics and outcome of VAP in patients with renal failure and/or on maintenance hemodialysis.
Material and Methods: A prospective observational study was conducted from February 2022 to February 2023. Patients >18 years, on mechanical ventilation (MV) for >48 hours, having underlying deranged renal function and who developed VAP were included. Demographics, cause of intubation, day of onset of VAP, clinical features, laboratory parameters and tracheal cultures were noted. Patients were followed till day 14 of VAP for mortality.
Results: Out of 165 MV patients, 67 (40.60%) developed VAP, 33 (49.25%) in ≤ 4 days. The cause of intubation was respiratory distress in 58(86.8%) patients. In 61(91%) patients tracheal cultures were positive with Acinetobacter species (64%) as the most common organism and 93% of which were carbapenem resistant. Carbapenem resistant organisms were more frequently in case of late onset VAP (91.2% versus 72.7% p=0.049). A total of 42 patients (62%) died, 76 % within 7 days of VAP and 13 patients (19.40%) recovered with successful extubation. There was no significant difference in 14 days mortality between early or late VAP.
Conclusion: VAP rates in patients with preexisting renal failure were 40%. Half of them developed in <4 days. Acinetobacter spp. was the predominant causative agent. Attributed mortality was high at 63% where two thirds of patients died within 14 days.
Keywords: Outcome, Renal failure, Ventilator associated pneumonia, Mechanical ventilator
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Muhammad Hassan, Zaheer Udin Babar, Sanjay Kumar, Muhammad Kashif Farooq, Sunil Kumar Dodani, Asma Nasim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.